NEW PODCAST!

The NASH Tsunami In Diabetes

Getting Ahead of the Rising Tide in Fatty Liver Disease

Recent prospective studies suggest that more than half of patients with Type 2 diabetes have concomitant NAFLD and more than one in three have NASH.

Other recent research tells us that patients with both diseases are at significantly increased risk of heart disease and cancer and are likely to have lower quality-of-life scores when compared to patients with T2D alone.

Join endocrinologist Kenneth Cusi, MD, forecaster/podcaster Roger Green, and their renowned guests to focus on the scale of the problem (HINT: large and scary!) and practical things you can do today to diagnose and treat these patients more effectively.

new podcast!! ⤵

S3-E1.2 - NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S3-E41 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
SurfingNASH.Com is honored to have the following sponsors

Would you like to participate ask a question join the surfers in our next episode?

S3-E38.1 – From the Vault: Why NASH Drug Trials Fail

Our 2nd anniversary look in the Vault starts with Jörn Schattenberg’s first episode as a featured guest, a 2020 episode reviewing his article on why NASH drug trials fail. One key focus was the proper design and use of Phase 2 trials.

S3-E37.5 – The Need to Focus on NASH Cirrhosis Patients

Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight surrounding NASH cirrhosis and cirrhosis patient care. This conversation sums up much of the previous discussion, with the conclusion that as diagnostic technologies and drugs in development improve, the need to communicate better with patients remains pivotal for successful therapies.

S3-E37.4 – The “Pincer Movement” In Cirrhosis Technology: Patient Support vs High-End MedTech

Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH cirrhosis. This conversation focuses on a “pincer movement” in the technology necessary to support cirrhosis patients: low-end technology to foster better patient communication and education, and high-end medical technology to diagnose, stage and treat the disease faster and more accurately.

S3-E37.3 – Where Is the Next Cirrhosis Breakthrough?

Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH cirrhosis. This conversation asks where we will find the next major breakthrough in treating cirrhosis patients.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.
Previous
Next

Experience Nudge Learning!
Interested in a new way of learning?